The treatment results were assigned to 8 and 6 treatment scenarios for FSC and CCH, respectively, taking into account possible complications (Chen et al. 2011) (Fig. 36.1). The study was based on the healthcare system in Spain. All relevant direct medical costs for both alternatives were collected in 2014 and in €. Unit costs were obtained from the Pharmacy Service and Accounting Department of the hospital. An analysis of sensitivity was performed by modifying the main variables to check the robustness of the results.

Cost collected for both groups were: initial traumatology visit at the clinic, wound healing, physiotherapy sessions, subsequent visits, recurrence and main complications. For the FSC group specific costs included were: general or plexus block anesthesia, preoperative tests and operating room costs. For the CCH group the costs were based on the acquisition, preparation and administration of the drug and local anesthesia costs for the extension of the finger. (De Salas-Cansado et al. 2013; Sanjuan-Cervero et al. 2013).

We calculated QALYs for each possible outcome by multiplying the mean utility assigned by the participants by 20 remaining life years (Chen et al. 2011). We calculated incremental cost-effectiveness ratios (ICER) by dividing the incremental costs of the intervention by the incremental benefits, such as €/QALYs (Husereau et al. 2013).